12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
Public ClinicalTrials.gov record NCT00240435. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison of 12-week Treatment of Two Doses (5 Mcg and 10 Mcg) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) i
Study identification
- NCT ID
- NCT00240435
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 491 participants
Conditions and interventions
Conditions
Interventions
- 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler Device
- 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler Device
Device
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2002
- Primary completion
- Nov 30, 2003
- Completion
- Not listed
- Last update posted
- Oct 31, 2013
Started 2002
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| Boehringer Ingelheim Investigational Site | Downey | California | — | — |
| University of California - Los Angeles | Los Angeles | California | — | — |
| Boehringer Ingelheim Investigational Site | Palo Alto | California | — | — |
| Rocky Mountain Center for Clinical Research | Wheat Ridge | Colorado | — | — |
| Boehringer Ingelheim Investigational Site | Bay Pines | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Wheaton | Maryland | — | — |
| Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| Boehringer Ingelheim Investigational Site | New Hyde Park | New York | — | — |
| Boehringer Ingelheim Investigational Site | Elizabeth City | North Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00240435, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2013 · Synced Jun 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00240435 live on ClinicalTrials.gov.